

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Odidi, et al.**

Serial No.: **10/561,700**

Filed: **November 10, 2006**



Confirmation No.: **8166**

Group No. **1611**

Examiner: **Purdy, Kyle A.**

Docket Number: **221904-1050**

For: **Proton-pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This information disclosure statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, and specifically:

☐ under 37 CFR 1.97(b), or
(within Three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

☒ under 37 CFR 1.97(c) together with either a:
☐ Statement Under 37 C.F.R. 1.97(e), or
☒ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before the final office action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with a:
☐ Statement under 37 CFR 1.97(e), and
☐ a \$180.00 petition fee set forth in 37 CFR 1.17(p).
(Filed after final office action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Enclosed is a check in the amount of \$

☒ Payment by credit card.

☐ Please charge \$ to deposit account

☒ At any time during the pendency of this application, please charge any fees required to Deposit Account 20-0778 pursuant to 37 CFR 1.25. The Commissioner is hereby requested to credit any overpayment to Deposit Account No. 20-0778.

☒ Applicant(s) submit herewith *Form PTO SB/08A-08B-08a - Information Disclosure Statement by Applicant* together with copies (where required) of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may or may not be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. As required by 37 C.F.R. §1.98(a), a legible copy of each document is provided.

06/14/2011 MBELETE1 00000015 10561700

01 FC:1806

180.00 0P

- ☐ A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form SB/08A-08B-08a, as presently understood by the individual(s) designated in 37 CFR 1.56(c) most knowledgeable about the content is given on the attached sheet, or where a foreign language patent is cited in a search report or other action by a foreign patent office in a counterpart foreign application, an English language version of the search report or action which indicates the degree of relevance found by the foreign office is listed on the form PTO SB/08A-08B-08a and is enclosed herewith.

The following rights are reserved by the Applicant(s): the right to establish the patentability of the claimed invention over any of the listed documents should they be applied as reference, and/or the right to prove that some of these documents may not be prior art, and/or the right to prove that some of these documents may not be enabling for the teachings they purport to offer.


This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present application does not exist. Any statements or identifications regarding the relevance of any portion(s) of cited references should not be construed as a representation that the most relevant portion(s) have been identified, and the absence of such statements or identifications should not be construed as representations that there are no relevant portion(s). The Examiner is specifically requested not to rely solely on the materials submitted herewith. The Examiner is requested to conduct an independent and thorough review of the documents, and to form independent opinions as to their significance.

It is requested that the information disclosed herein be made of record in this application and that the Examiner initial and return a copy of the enclosed PTO SB/08A-08B-08a to indicate the documents have been considered.

Respectfully Submitted,

**THOMAS, KAYDEN, HORSTEMEYER
& RISLEY, L.L.P.**

By:



Christopher B. Linder, Reg. No.: 47,751

600 Galleria Parkway, S.E.
Suite 1500
Atlanta, Georgia 30339-5994
Phone: (770) 933-9500
Fax: (770) 951-0933

CUSTOMER NO: 24504



CERTIFICATE OF MAILING

I hereby certify that the below listed items are being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

**Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**

on June 9, 2011

Jo Bryan

In re application of: **Odidi, et al.**

Confirmation No.: **8166**

Serial No.: **10/561,700**

Group No. **1611**

Filed: **November 10, 2006**

Examiner: **Purdy, Kyle A.**

Docket Number: **221904-1050**

For: **PROTON-PUMP-INHIBITOR-CONTAINING CAPSULES WHICH COMPRISE
SUBUNITS DIFFERENTLY STRUCTURED FOR A DELAYED RELEASE OF
THE ACTIVE INGREDIENT**

The following is a list of documents enclosed:

Return Postcard
Information Disclosure Statement
Credit Card Authorization in the Amount of \$180.00
SBO8a (39 pages)
91 non-patent references attached

Further, the Commissioner is authorized to charge Deposit Account No. 20-0778 for any additional fees required. The Commissioner is requested to credit any excess fee paid to Deposit Account No. 20-0778.